Venetoclax | Venetoclax : BH3 mimetic inhibitor of BCL2
RATINGS:
Cellular Use: (3 reviews)

In Model Organisms: (3 reviews)
Control Compounds

Probe Summary

Targets Biochemical/Biophysical Potency Cellular Potency
BCL2
  • Ki:<0.010 nM
  • EC50:4 nM
BH3 mimetic
--

Selectivity

In Vitro Selectivity Assessment

Potency: Ki - BCL-XL: 48 nM, BCL-W: 245 nM; MCL-1: >444 nM

Potency Assay Off-Target:
TR-FRET
Selectivity Assessment Description:
Not available

Potency
Cellular
In Vitro

BCL2

Mode of Action: BH3 mimetic

Structure-Activity-Relationship data available? No

In Vivo Validations

Mouse
Dose: 12.5 mg/kg
Route of delivery: Oral
Organ of interest (O): Hemotological xenografts: RS4;11 cells

Reference: --

Chemical Information

Molecular Formula C45H50ClN7O7S
SMILEs CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1
InChI InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54)
Molecular weight 867.32 Da
AlogP 8.6599
HBond acceptors 14
HBond donors 3
Atoms 111

Vendors

Note: This is not an exhaustive list and does not indicate endorsement by the portal.

Expert Reviews


(on 11 Apr 2017 )
Cellular Use Rating
In Model Organisms
( The reviewer did not leave any comments )
(on 12 Apr 2017 )
Cellular Use Rating
In Model Organisms
( The reviewer did not leave any comments )
(on 11 Nov 2020 )
Cellular Use Rating
In Model Organisms
Early studies with Venetoclax (ABT-199), a potent and selective orally-bioavailable B-cell lymphoma 2 small-molecule inhibitor, which has shown an remarkable response across a number of hematologic...
Note: The Chemical Probes Portal only endorses compounds as chemical probes for use as specific and selective modulators of the proposed target if they receive three or more (3-4) stars. Read more about our evaluation criteria